Concord Biotech Ltd logo

Concord Biotech Ltd

CONCORDBIO NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹16,205 Cr
Volatility
High Risk
P/E Ratio
58.12
EBITDA
₹420 Cr
Return on Equity
12.86%
Debt to Equity
0
Book Value
₹192.81
EPS
₹29.94
52W High
₹1,801.9
52W Low
₹987

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Concord Biotech Ltd insights

58 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 28.2%

Weaknesses

3
  • Stock is trading at 7.85 times its book value
  • The company has delivered a poor sales growth of 11.3% over past five years.
  • Company has high debtors of 159 days.

Growth Rate

Revenue Growth
-11.03% ↗
Net Income Growth
-30.25% ↗
Cash Flow Change
9.14% ↗
ROE
-37.27% ↘
ROCE
-37.59% ↘
EBITDA Margin (Avg.)
-14.35% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk medium

Concord Biotech Ltd is a niche fermentation-based API company trading at a market cap of ₹14,982 Cr and PE of 55.4x. FY26 revenue declined 12.1% YoY to ₹1,055 Cr after an 18% growth in FY25, while the TTM profit has contracted 20%. The company remains virtually debt-free with a 42% EBITDA margin profile, but faces near-term headwinds on topline growth and elevated valuation multiples.

Bull Case 8
  • Virtually debt-free balance sheet provides financial flexibility and lower risk during cyclical downturns
  • EBITDA margin of 42.2% in FY25 (44.3% in Q4 FY25) indicates strong pricing power in niche fermentation-based APIs
  • Formulation segment grew 38% YoY in FY25 with management guiding 35% CAGR, now contributing 22% of revenue vs 19% in FY24
  • 10-year compounded sales CAGR of 14% demonstrates a long-term structural growth trajectory in specialty pharma
  • 118 new customer additions in the API segment in FY25 signals expanding market reach and diversification
  • Healthy dividend payout ratio of 28.2% with current yield of 0.52%, showing shareholder return commitment
  • Strategic diversification beyond immunosuppressants into anti-infective and anti-fungal APIs with plans to launch 2-3 new APIs annually
  • API CDMO segment scaling up with one project commercialized and several in advanced stages, opening a new revenue stream
Bear Case 8
  • FY26 revenue declined 12.1% YoY to ₹1,055 Cr, and Q4 FY26 revenue fell 24.1% YoY to ₹326 Cr, signaling sharp near-term deceleration
  • TTM profit has contracted 20%, with Q4 FY26 profit down 37% YoY, raising concerns about earnings sustainability
  • PE ratio of 55.4x is expensive relative to the healthcare sector median, especially given negative recent growth
  • Trading at 7.49x price-to-book value, reflecting rich premium that leaves limited margin of safety
  • 5-year compounded profit CAGR of just 1% shows earnings have not kept pace with the stock's premium valuation
  • High debtor days of 159 days indicate stretched working capital and potential collection risk
  • ROE declined from 3-year average of 18% to 13% in the last year, suggesting deteriorating return efficiency
  • Stock has delivered -12% returns over the past 1 year, underperforming the broader market amid growth concerns

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 20h ago
Positives 2
  • Q1FY27 profit surges 44% Jul 31

    Standalone net profit jumped to ₹612M from ₹425M YoY. EBITDA margin expanded to 33.46% from 30.1%, reflecting improved operational efficiency.

  • Revenue up 26%, exports jump 46% Aug 1

    Q1FY27 consolidated revenue grew 26% to ₹257.5 crore driven by API sales. Exports surged 46% while EBITDA rose 34% to ₹82.4 crore.

Neutral 2
  • AGM passes all six resolutions Aug 1

    Shareholders approved all six resolutions at the 41st AGM on July 31, 2026. The special resolution to enhance subsidiary loan limits passed with 81.64% support despite promoter abstention.

  • Q1FY27 earnings call hosted Aug 3

    Concord Biotech conducted its Q1FY27 earnings call on August 3, 2026 to discuss standalone and consolidated results and business outlook.

TL;DR: Concord Biotech delivered a strong Q1FY27 with broad-based growth across revenue, profits, and margins. Export momentum at 46% growth and EBITDA margin expansion to 33.46% signal improving operating leverage. No material headwinds are visible in recent news flow. The trend is clearly improving, with API-led growth and international expansion providing a solid runway.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
195
262
241
319
216
310
244
430
204
247
278
326
261
Expenses
123
143
135
185
135
174
146
239
143
157
176
204
173
Operating Profit
72
119
106
134
81
137
98
190
61
91
102
122
87
OPM %
37%
45%
44%
42%
38%
44%
40%
44%
30%
37%
37%
38%
33%
Other Income
7
8
8
11
10
10
15
9
14
13
7
16
13
Interest
1
1
0
0
0
0
0
0
0
0
0
0
0
Depreciation
13
13
14
14
13
13
13
15
18
18
19
19
18
PBT
65
113
100
131
78
133
99
185
57
86
90
118
82
Tax %
25%
25%
26%
26%
25%
26%
25%
23%
26%
26%
25%
24%
26%
Net Profit
48
84
75
97
58
99
74
142
43
63
68
90
61
EPS in Rs
4.63
8.08
7.13
9.29
5.57
9.43
7.08
13.57
4.07
6.01
6.48
8.6
5.85
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
239
276
340
436
512
617
713
853
1,017
1,200
1,055
1,112
Expenses
133
145
212
256
308
289
439
509
585
693
678
709
Operating Profit
105
131
127
180
205
328
274
344
432
507
377
402
OPM %
44%
48%
37%
41%
40%
53%
38%
40%
42%
42%
36%
36%
Other Income
11
8
36
17
31
14
23
35
34
44
49
49
Interest
1
0
1
1
1
1
6
5
3
1
1
0
Depreciation
10
10
18
19
21
28
50
54
54
54
74
75
PBT
106
129
144
178
213
313
241
320
409
496
351
376
Tax %
34%
33%
30%
33%
21%
25%
26%
26%
26%
25%
25%
—
Net Profit
70
87
100
118
169
235
179
238
305
373
263
282
EPS in Rs
76.32
94.78
106
124
178
247
188
22.76
29.13
35.65
25.17
26.94
Div. Payout %
22%
25%
0%
21%
22%
0%
3%
30%
30%
25%
30%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
9
9
10
10
10
10
10
10
10
10
10
Reserves
268
329
585
673
761
990
1,098
1,282
1,515
1,802
2,009
Borrowings
35
36
22
9
52
89
62
32
10
3
1
Other Liabilities
55
74
69
71
118
94
144
191
164
219
216
Total Liabilities
367
448
685
763
941
1,183
1,313
1,515
1,699
2,034
2,237
Fixed Assets
104
110
189
230
240
546
573
593
575
795
786
CWIP
19
70
3
19
141
18
74
173
211
51
79
Investments
42
43
151
229
199
142
74
138
244
335
488
Other Assets
202
225
343
285
361
477
592
611
668
854
883
Total Assets
367
448
685
763
941
1,183
1,313
1,515
1,699
2,034
2,237
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
—
—
79
—
155
167
207
246
265
245
264
Investing
—
—
-42
—
-114
-195
-112
-158
-155
-160
-142
Financing
—
—
-37
—
-43
31
-100
-85
-99
-99
-115
Net Cash Flow
—
—
0
—
-1
3
-4
3
12
-14
7
Free Cash Flow
—
—
79
—
-1
-37
52
101
180
134
169
CFO/OP
—
—
101
—
100
74
98
92
85
70
96
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
165
182
236
133
131
105
119
117
125
159
159
Inventory Days
276
321
381
310
312
503
434
430
331
286
483
Days Payable
108
129
210
112
201
152
185
190
150
135
150
Cash Conversion Cycle
334
374
407
331
242
456
368
357
306
310
492
Working Capital Days
195
209
275
177
159
177
163
153
166
193
231
ROCE %
—
37%
—
25%
25%
32%
21%
26%
28%
28%
17%

Shareholding Pattern

As of Jun 2026
Promoters 44.08%
Others 30.81%
DIIs 9.36%
Public 8.23%
FIIs 7.52%
Total 100.00%
  Aug 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
FIIs
0.00%
7.30%
0.00%
6.48%
7.11%
8.10%
8.33%
9.35%
9.11%
8.03%
7.58%
7.80%
7.52%
DIIs
4.89%
8.18%
8.13%
8.46%
10.40%
9.89%
9.66%
9.16%
8.87%
9.55%
9.58%
9.22%
9.36%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
13.33%
6.78%
6.76%
7.08%
7.64%
7.33%
7.33%
6.94%
7.43%
7.77%
8.11%
8.09%
8.23%
Others
37.69%
33.66%
41.03%
33.90%
30.76%
30.61%
30.59%
30.47%
30.51%
30.56%
30.64%
30.81%
30.81%
No. of Shareholders
3,77,572
1,00,927
87,486
83,296
80,737
84,298
82,004
81,219
82,045
82,650
81,815
82,249
83,325

Documents

Frequently Asked Questions about Concord Biotech Ltd

What does Concord Biotech Ltd do?
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]
Where is Concord Biotech Ltd (CONCORDBIO) listed?
Concord Biotech Ltd is listed on the Indian stock exchanges. It is listed on NSE: CONCORDBIO and BSE: 543960. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Concord Biotech Ltd belong to?
Concord Biotech Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Concord Biotech Ltd?
Concord Biotech Ltd has a market capitalisation of approximately ₹16205.05 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Concord Biotech Ltd?
The Price-to-Earnings (PE) ratio of Concord Biotech Ltd is 58.12. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Concord Biotech Ltd?
Over the past 52 weeks, Concord Biotech Ltd has traded between a low of ₹987 and a high of ₹1,801.9. This range helps investors understand the stock's price volatility and recent trading levels.
Does Concord Biotech Ltd pay dividends?
Yes, Concord Biotech Ltd has a dividend yield of 0.50%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Concord Biotech Ltd?
Concord Biotech Ltd has a Return on Equity (ROE) of 12.86%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Concord Biotech Ltd on Tapetide?
On Tapetide, you can view Concord Biotech Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Website concordbiotech.com
CEO Mr. Sudhir Jairam Vaid
Employees 1,571
Listed 2023-08-18
Face Value ₹ 1
Issued Size 10,46,16,204

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List